Lipoxins,Resolvins, Protectins,Maresins, and Nitrolipids: Connecting Lipids,Inflammation, and Cardiovascular Disease Risk |
| |
Authors: | Undurti N Das |
| |
Institution: | (1) Jawaharlal Nehru Technological University, Kakinada, 533 003, India;(2) UND Life Sciences, 13800 Fairhill Road, #321, Shaker Heights, OH 44120, USA |
| |
Abstract: | Essential fatty acids and their metabolites (γ-linolenic acid GLA], dihomo-GLA, arachidonic acid, eicosapentaenoic acid,
and docosahexaenoic acid; prostaglandin E1; prostacyclin PGI2]; PGI3; lipoxins; resolvins; protectins; maresins; and nitrolipids) prevent platelet aggregation, produce vascular relaxation, inhibit
neutrophil degranulation and superoxide formation, inhibit platelet activation, possess peroxisome proliferator-activated
receptor-γ ligand activity, and release nitric oxide. Thus, they lower blood pressure, are anti-arrhythmic and anti-inflammatory
in nature, reduce low-density lipoprotein cholesterol, ameliorate the adverse actions of homocysteine, activate telomerase,
and have cytoprotective properties—actions that prevent atherosclerosis and cardiovascular disease. Because coronary heart
disease (CHD) and atherosclerosis are low-grade systemic inflammatory conditions, it is likely that reduced formation of lipoxins,
resolvins, protectins, maresins, and nitrolipids plays a significant role in the pathogenesis of CHD. Hence, development of
stable synthetic analogues of lipoxins, resolvins, protectins, and maresins may form a new therapeutic approach to CHD and
other low-grade systemic inflammatory conditions. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|